GILD - Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry | Benzinga
Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Gilead Sciences (NASDAQ:GILD) in comparison to its major competitors within the Biotechnology industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Gilead Sciences Background
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | |||||||
| 18.03 | |||||||
| 4.62 | |||||||
| 3.61 | |||||||
| 4.96% | |||||||
| $2.5 | |||||||
| $5.16 | |||||||
| 5.42% | |||||||
| AbbVie Inc | |||||||
| 29.94 | |||||||
| 19.96 | |||||||
| 4.61 | |||||||
| 15.4% | |||||||
| $5.42 | |||||||
| $9.62 | |||||||
| -4.92% | |||||||
| Amgen Inc | |||||||
| 18.91 | |||||||
| 22.13 | |||||||
| 5.67 | |||||||
| 22.74% | |||||||
| $3.26 | |||||||
| $5.17 | |||||||
| 5.94% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 28.19 | |||||||
| 6.09 | |||||||
| 9.98 | |||||||
| 6.12% | |||||||
| $1.21 | |||||||
| $2.18 | |||||||
| 13.52% | |||||||
| Regeneron Pharmaceuticals Inc | |||||||
| 21.38 | |||||||
| 3.65 | |||||||
| 7.25 | |||||||
| 4.08% | |||||||
| $1.2 | |||||||
| $2.75 | |||||||
| 10.53% | |||||||
| Biogen Inc | |||||||
| 14.03 | |||||||
| 2.58 | |||||||
| 3.75 | |||||||
| 4.19% | |||||||
| $0.87 | |||||||
| $1.86 | |||||||
| -5.14% | |||||||
| Moderna Inc | |||||||
| 28.60 | |||||||
| 1.85 | |||||||
| 3.10 | |||||||
| -7.71% | |||||||
| $-1.64 | |||||||
| $-0.41 | |||||||
| -93.08% | |||||||
| BioNTech SE | |||||||
| 4.88 | |||||||
| 1.06 | |||||||
| 2.32 | |||||||
| -0.95% | |||||||
| $-0.38 | |||||||
| $-0.37 | |||||||
| -94.75% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 158.83 | |||||||
| 3.25 | |||||||
| 7.05 | |||||||
| 1.19% | |||||||
| $0.1 | |||||||
| $0.47 | |||||||
| 11.52% | |||||||
| Incyte Corp | |||||||
| 34.13 | |||||||
| 2.63 | |||||||
| 3.56 | |||||||
| 4.42% | |||||||
| $0.3 | |||||||
| $0.89 | |||||||
| 4.74% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 62.43 | |||||||
| 5.86 | |||||||
| 6.73 | |||||||
| 5.4% | |||||||
| $0.13 | |||||||
| $0.44 | |||||||
| 19.7% | |||||||
| United Therapeutics Corp | |||||||
| 12.79 | |||||||
| 1.96 | |||||||
| 5.28 | |||||||
| 4.92% | |||||||
| $0.36 | |||||||
| $0.53 | |||||||
| 27.76% | |||||||
| Exelixis Inc | |||||||
| 41.66 | |||||||
| 2.62 | |||||||
| 3.96 | |||||||
| 3.19% | |||||||
| $0.08 | |||||||
| $0.45 | |||||||
| 12.02% | |||||||
| Grifols SA | |||||||
| 45.23 | |||||||
| 0.90 | |||||||
| 0.81 | |||||||
| 1.02% | |||||||
| $0.25 | |||||||
| $0.62 | |||||||
| 7.81% | |||||||
| Average | |||||||
| 38.54 | |||||||
| 5.73 | |||||||
| 4.93 | |||||||
| 4.92% | |||||||
| $0.86 | |||||||
| $1.86 | |||||||
| -6.49% |